Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Microbiome swings with repeated insults.

Rashidi A, Maeser D, Kaiser T, Ebadi M, Rehman TU, Holtan SG, Weisdorf DJ, Khoruts A, Staley C.

Br J Haematol. 2020 Feb 10. doi: 10.1111/bjh.16509. [Epub ahead of print] No abstract available.

PMID:
32043276
2.

Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation.

Rashidi A, Kaiser T, Graiziger C, Holtan SG, Rehman TU, Weisdorf DJ, Dunny GM, Khoruts A, Staley C.

Cancer. 2019 Dec 24. doi: 10.1002/cncr.32641. [Epub ahead of print]

PMID:
31873965
3.

Levaquin Gets a Pass.

Rashidi A, Kaiser T, Holtan SG, Rehman TU, Weisdorf DJ, Khoruts A, Staley C.

Biol Blood Marrow Transplant. 2019 Dec 20. pii: S1083-8791(19)31651-9. doi: 10.1016/j.bbmt.2019.12.722. [Epub ahead of print]

PMID:
31870930
4.

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.

Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML.

Blood. 2020 Jan 9;135(2):97-107. doi: 10.1182/blood.2019003125.

PMID:
31738834
5.

Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.

Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG.

Biol Blood Marrow Transplant. 2020 Mar;26(3):606-611. doi: 10.1016/j.bbmt.2019.11.006. Epub 2019 Nov 10.

PMID:
31715306
6.

Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy.

Rashidi A, Zhu Z, Kaiser T, Manias DA, Holtan SG, Rehman TU, Weisdorf DJ, Khoruts A, Dunny GM, Staley C.

PLoS One. 2019 Oct 10;14(10):e0223890. doi: 10.1371/journal.pone.0223890. eCollection 2019.

7.

Pediatric acute GVHD: clinical phenotype and response to upfront steroids.

MacMillan ML, Holtan SG, Rashidi A, DeFor TE, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2020 Jan;55(1):165-171. doi: 10.1038/s41409-019-0651-9. Epub 2019 Sep 2.

8.

Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy.

Rashidi A, Kaiser T, Graiziger C, Holtan SG, Rehman TU, Weisdorf DJ, Khoruts A, Staley C.

Leukemia. 2020 Jan;34(1):312-316. doi: 10.1038/s41375-019-0547-0. Epub 2019 Aug 22. No abstract available.

PMID:
31439944
9.

Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients.

Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, Holtan SG, Jurdi NE, Thyagarajan B, Brunstein CG, Bachanova V, Warlick ED, Severseike B, Te HS, Lund T, Arora M.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2454-2460. doi: 10.1016/j.bbmt.2019.07.030. Epub 2019 Aug 5.

10.

Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, Amin K, Vaughn BP, Howard J, Khoruts A, Arora M, DeFor TE, Johnson D, Blazar BR, Weisdorf DJ, Wang J.

JCI Insight. 2019 Aug 8;5. pii: 129762. doi: 10.1172/jci.insight.129762.

11.

Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.

Rashidi A, DeFor TE, Holtan SG, Blazar BR, Weisdorf DJ, MacMillan ML.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2297-2302. doi: 10.1016/j.bbmt.2019.07.017. Epub 2019 Jul 17.

PMID:
31325587
12.

Validation of Minnesota acute graft-versus-host disease Risk Score.

MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ.

Haematologica. 2020 Jan 31;105(2):519-524. doi: 10.3324/haematol.2019.220970. Print 2020.

13.

Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.

Holtan SG, Zhang L, DeFor TE, Bejanyan N, Arora M, Rashidi A, Lazaryan A, Kotiso F, Blazar BR, Wagner JE, Brunstein CG, MacMillan ML, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1884-1889. doi: 10.1016/j.bbmt.2019.05.015. Epub 2019 May 22.

PMID:
31128328
14.

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ.

Blood Adv. 2019 May 14;3(9):1441-1449. doi: 10.1182/bloodadvances.2018030171.

15.

Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia.

Hegerova L, He F, Zantek ND, Vercellotti GM, Holtan SG, Reding MT.

Blood Cells Mol Dis. 2019 Jul;77:109-112. doi: 10.1016/j.bcmd.2019.04.009. Epub 2019 Apr 18.

PMID:
31029024
16.

Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia.

Rashidi A, Kaiser T, Shields-Cutler R, Graiziger C, Holtan SG, Rehman TU, Wasko J, Weisdorf DJ, Dunny G, Khoruts A, Staley C.

Sci Rep. 2019 Apr 15;9(1):6083. doi: 10.1038/s41598-019-42652-6.

17.

Host and Graft Factors Impacting Infection Risk in Hematopoietic Cell Transplantation.

Kao RL, Holtan SG.

Infect Dis Clin North Am. 2019 Jun;33(2):311-329. doi: 10.1016/j.idc.2019.02.001. Epub 2019 Mar 30. Review.

PMID:
30940461
18.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
19.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

20.

Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2019 May;25(5):883-890. doi: 10.1016/j.bbmt.2019.01.003. Epub 2019 Jan 6.

PMID:
30625388
21.

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease.

Watson AP, Brunstein CG, Holtan SG.

Case Rep Transplant. 2018 Nov 4;2018:4539757. doi: 10.1155/2018/4539757. eCollection 2018.

22.

Pre-transplant recovery of microbiome diversity without recovery of the original microbiome.

Rashidi A, Kaiser T, Holtan SG, Weisdorf DJ, Khoruts A, Staley C.

Bone Marrow Transplant. 2019 Jul;54(7):1115-1117. doi: 10.1038/s41409-018-0414-z. Epub 2018 Nov 29. No abstract available.

PMID:
30498199
23.

Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease.

Rashidi A, Shanley R, Holtan SG, MacMillan ML, Blazar BR, Khoruts A, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2190-2196. doi: 10.1016/j.bbmt.2018.06.036. Epub 2018 Jul 7.

24.

Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid.

Amin K, Yaqoob U, Schultz B, Vaughn BP, Khoruts A, Howard JR, DeFor TE, Forster C, Meyer C, Gandhi I, Weisdorf DJ, Rashidi A, MacMillan ML, Blazar BR, Panoskaltsis-Mortari A, Holtan SG.

Mod Pathol. 2019 Apr;32(4):560-567. doi: 10.1038/s41379-018-0170-z. Epub 2018 Nov 13.

PMID:
30425334
25.

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.

Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 Feb;25(2):270-278. doi: 10.1016/j.bbmt.2018.09.004. Epub 2018 Oct 3.

26.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

27.

Antibiotic practice patterns in hematopoietic cell transplantation: A survey of blood and marrow transplant clinical trials network centers.

Rashidi A, Wangjam T, Bhatt AS, Weisdorf DJ, Holtan SG; BMT CTN Investigators.

Am J Hematol. 2018 Nov;93(11):E348-E350. doi: 10.1002/ajh.25236. Epub 2018 Sep 9. No abstract available.

28.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

29.

Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions.

He FC, Holtan SG.

Curr Hematol Malig Rep. 2018 Feb;13(1):44-52. doi: 10.1007/s11899-018-0433-2. Review.

PMID:
29388008
30.

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG.

Bone Marrow Transplant. 2018 Jan;53(1):64-68. doi: 10.1038/bmt.2017.236. Epub 2017 Oct 23.

31.

Vorinostat is victorious in GVHD prevention.

Holtan SG, Weisdorf DJ.

Blood. 2017 Oct 12;130(15):1690-1691. doi: 10.1182/blood-2017-08-802249. No abstract available. Erratum in: Blood. 2017 Dec 21;130(25):2810.

PMID:
29025718
32.

Whole-Body Distribution of Leukemia and Functional Total Marrow Irradiation Based on FLT-PET and Dual-Energy CT.

Magome T, Froelich J, Holtan SG, Takahashi Y, Verneris MR, Brown K, Dusenbery K, Wong J, Hui SK.

Mol Imaging. 2017 Jan-Dec;16:1536012117732203. doi: 10.1177/1536012117732203.

33.

Early assessment of dosimetric and biological differences of total marrow irradiation versus total body irradiation in rodents.

Hui S, Takahashi Y, Holtan SG, Azimi R, Seelig D, Yagi M, Ingvalson J, Alaei P, Sharkey L, Kodal B, Peterson N, Meyer C, Godin L, Ehrhardt M, Storme G, Zhou D, Panoskaltsis-Mortari A.

Radiother Oncol. 2017 Sep;124(3):468-474. doi: 10.1016/j.radonc.2017.07.018. Epub 2017 Aug 1.

34.

PlGF enhances TLR-dependent inflammatory responses in human mononuclear phagocytes.

Newell LF, Holtan SG, Yates JE, Pereira L, Tyner JW, Burd I, Bagby GC.

Am J Reprod Immunol. 2017 Oct;78(4). doi: 10.1111/aji.12709. Epub 2017 Jun 20.

35.

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A.

Bone Marrow Transplant. 2017 Sep;52(9):1300-1303. doi: 10.1038/bmt.2017.89. Epub 2017 Jun 5.

36.

The Perfect Transplant.

Holtan SG.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1044-1045. doi: 10.1016/j.bbmt.2017.05.010. Epub 2017 May 11. No abstract available.

37.

Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Hui S, Brunstein C, Takahashi Y, DeFor T, Holtan SG, Bachanova V, Wilke C, Zuro D, Ustun C, Weisdorf D, Dusenbery K, Verneris MR.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1110-1116. doi: 10.1016/j.bbmt.2017.04.002. Epub 2017 Apr 7.

38.

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation.

He F, Verneris MR, Cooley S, Blazar BR, MacMillan ML, Newell LF, Panoskaltsis-Mortari A, DeFor T, Weisdorf DJ, Holtan SG.

Bone Marrow Transplant. 2017 Feb;52(2):301-303. doi: 10.1038/bmt.2016.261. Epub 2016 Nov 21. No abstract available.

39.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers MED, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JLM, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J.

Blood. 2016 Nov 10;128(19):2350-2358. doi: 10.1182/blood-2015-09-669846. Epub 2016 Sep 13.

40.

Placental growth factor: What hematologists need to know.

Newell LF, Holtan SG.

Blood Rev. 2017 Jan;31(1):57-62. doi: 10.1016/j.blre.2016.08.004. Epub 2016 Aug 27. Review.

41.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2025-2030. doi: 10.1016/j.bbmt.2016.08.005. Epub 2016 Aug 9.

42.

Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota.

Khoruts A, Hippen KL, Lemire AM, Holtan SG, Knights D, Young JH.

Transl Res. 2017 Jan;179:116-125. doi: 10.1016/j.trsl.2016.07.013. Epub 2016 Jul 25. Review.

43.

Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.

Enninga EA, Nevala WK, Holtan SG, Leontovich AA, Markovic SN.

Melanoma Res. 2016 Oct;26(5):429-41. doi: 10.1097/CMR.0000000000000281.

44.

Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.

Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG.

Haematologica. 2016 Jun;101(6):764-72. doi: 10.3324/haematol.2015.138990. Epub 2016 Apr 1.

45.

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, Lee SJ, Wolff D, Subrt P, Abdossamadi S, Sung S, Storek J, Levings M, Aljurf M, Arora M, Cutler C, Gallagher G, Kuruvilla J, Lipton J, Nevill TJ, Newell LF, Panzarella T, Pidala J, Popradi G, Szwajcer D, Tay J, Toze CL, Walker I, Couban S, Storer BE, Schultz KR.

Blood. 2016 Jun 16;127(24):3082-91. doi: 10.1182/blood-2015-09-668251. Epub 2016 Mar 28.

46.

Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease.

Knorr DA, Wang H, Aurora M, MacMillan ML, Holtan SG, Bergerson R, Cao Q, Weisdorf DJ, Cooley S, Brunstein C, Miller JS, Wagner JE, Blazar BR, Verneris MR.

Biol Blood Marrow Transplant. 2016 May;22(5):825-33. doi: 10.1016/j.bbmt.2016.01.003. Epub 2016 Jan 13.

47.

Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen.

Wilke C, Holtan SG, Sharkey L, DeFor T, Arora M, Premakanthan P, Yohe S, Vagge S, Zhou D, Holter Chakrabarty JL, Mahe M, Corvo R, Dusenbery K, Storme G, Weisdorf DJ, Verneris MR, Hui S.

Radiother Oncol. 2016 Jan;118(1):65-71. doi: 10.1016/j.radonc.2015.11.012. Epub 2015 Nov 30.

48.

A risk-adapted approach to acute GVHD treatment: are we there yet?

Holtan SG, MacMillan ML.

Bone Marrow Transplant. 2016 Feb;51(2):172-5. doi: 10.1038/bmt.2015.261. Epub 2015 Nov 9. Review.

PMID:
26551780
49.

Urinary-derived human chorionic gonadotropin to induce tolerance and promote healing in steroid-refractory GvHD.

Holtan SG, Panoskaltsis-Mortari A.

Bone Marrow Transplant. 2016 Jan;51(1):142-3. doi: 10.1038/bmt.2015.220. Epub 2015 Sep 21. No abstract available.

PMID:
26389834
50.

Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics.

Enninga EA, Nevala WK, Holtan SG, Markovic SN.

Front Immunol. 2015 Aug 26;6:424. doi: 10.3389/fimmu.2015.00424. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center